Compugen secures licensing deal with Gilead for IL-18 protein antibody cancer program, with $60M upfront

Com­pu­gen is set to re­ceive an up­front pay­ment of $60 mil­lion from Gilead to kick­start an ex­clu­sive li­cens­ing deal for the biotech’s an­ti-in­ter­leukin-18 pro­tein bind­ing an­ti­body pro­gram for sol­id tu­mors, in­clud­ing the pre­clin­i­cal can­di­date COM503.

Ac­cord­ing to the com­pa­nies, the li­cens­ing deal is worth $848 mil­lion, with Com­pu­gen set to re­ceive an ad­di­tion­al $30 mil­lion next year if COM503 se­cures an IND and a fur­ther $758 mil­lion in to­tal that cov­ers fu­ture de­vel­op­ment, reg­u­la­to­ry and com­mer­cial mile­stones. Al­so in store for Com­pu­gen are “sin­gle-dig­it to low dou­ble-dig­it tiered roy­al­ty pay­ments” for net sales world­wide.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.